Morepen Strengthens Integrated CDMO Capabilities with First U.S. ANDA Submission for Sitagliptin Tablets
First U.S. ANDA submitted for Sitagliptin Tablets USP in three strengths Strengthens formulation, bioequivalence and regulatory dossier capabilities Supports specialized
Read More